Pemitini (Pemigatinib) 4.5mg*42 | TLPH Laos Generic | GLT

Generic Information: Pemitini (Pemigatinib) 4.5mg — Laos

Pemitini is a Lao-manufactured generic of pemigatinib produced by Trans Continental Life Science & Pharmaceuticals (TLPH), a Laos-based pharmaceutical manufacturer. Unlike the originator's 14-tablet packs, Pemitini is supplied as 4.5 mg tablets in a larger 42-tablet bottle — a bulk presentation that reduces the frequency of re-ordering for patients on long-term therapy. TLPH uses the abbreviation "TLPH" on packaging and trade documents, so buyers should recognise both the full company name and the short form when verifying a batch.

Pemigatinib's standard dosing is 13.5 mg once daily on a 14-days-on/7-days-off cycle, so the 4.5 mg strength in a 42-tablet pack is typically used across dose adjustment or as a convenient multi-week supply at reduced doses. Patients should confirm their exact prescribed strength and schedule with their oncologist before ordering.

What Is Pemitini Used For?

Pemitini is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or rearrangement. Cholangiocarcinoma is a rare bile duct cancer with few effective treatments, and pemigatinib is the first targeted therapy developed for the FGFR2-altered subset, providing an oral option where chemotherapy offers limited benefit.

How Does Pemitini Work?

Pemigatinib, the active ingredient in Pemitini, selectively inhibits FGFR1, FGFR2 and FGFR3 tyrosine kinases. In tumours with an FGFR2 fusion or rearrangement, the receptor is constitutively active and drives cancer cell growth. Pemitini blocks this signalling, interrupting the proliferative and survival signals that depend on aberrant FGFR activation.

Indications

• Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, confirmed by a validated test.
• Adult patients who have progressed after at least one prior line of systemic therapy.

Dosage and Administration

The recommended pemigatinib dose is 13.5 mg once daily for 14 days followed by 7 days off, repeated in 21-day cycles. Tablets are taken orally with or without food and swallowed whole. The 4.5 mg strength supports dose adjustments. Phosphate, renal function and eye health should be monitored throughout treatment.

Side Effects

Common adverse reactions include hyperphosphatemia, diarrhoea, stomatitis, dry mouth, fatigue, nausea and alopecia. Serous retinal detachment is a serious, boxed-warning risk that requires prompt reporting of visual changes and ophthalmologic monitoring. Dry eye, nail changes and liver enzyme elevations may also occur.

Storage

Store Pemitini below 25°C in the original bottle, in a dry place away from direct light, and out of the reach of children. Use before the expiry date printed on the label.

Why Choose the GLT?

GLT verifies every Pemitini batch against the manufacturer's documentation and offers a transparent supply route for Lao generics. Lao-made pemigatinib is typically several times cheaper than the branded originator in Western markets, which makes long-term FGFR-targeted treatment far more affordable. We provide clear purchase documentation and direct, responsive support from inquiry through delivery.

How to Order Pemitini from GLT

Message GLT on WhatsApp at +86 15234153837 or email [email protected] to order Pemitini 4.5 mg (42 tablets). Tell us your quantity, destination and order type, and we confirm availability, batch details and shipping terms before dispatch.

FAQ

What is the difference between Pemitini and Pemazyre? Pemitini is a Lao generic of pemigatinib by TLPH, supplied in a 42-tablet bottle; Pemazyre is the Incyte originator in 14-tablet packs.

Why is Pemitini a 42-tablet pack? The larger pack size reduces re-ordering frequency for patients on long-term therapy, especially at adjusted doses.

Where can I order Pemitini? GLT supplies Pemitini internationally; contact us on WhatsApp or email for availability.